|Videos|April 25, 2017

How Do Respiratory Viral Infections Impact Pediatric Patients?

Matt Linam, MD, MS, Assistant Professor, Pediatric Infectious Diseases, University of Arkansas for Medical Sciences, explains the impact of respiratory viral infections in children.

Matt Linam, MD, MS, Assistant Professor, Pediatric Infectious Diseases, University of Arkansas for Medical Sciences, explains the impact of respiratory viral infections in children.

Interview Transcript (slightly modified for readability)

“Respiratory viral healthcare-associated infections can have a significant impact in children, especially in those that are immunosuppressed, like patients receiving chemotherapy, or infants in the Neonatal Intensive Care Unit, or the cardiovascular unit. Children that have underlying heart and lung disease, all of these are children who are at increased risk for having significant morbidity and sometimes even mortality. What for the rest of us may seem like the common cold, for them may actually prolong hospitalization, can increase their respiratory support requirements, delay their hospitalizations, and can cause some big problems.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.